Patents by Inventor Brian John Sutton

Brian John Sutton has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20250011473
    Abstract: The present invention relates to the area of improved anti-IgE antibodies and antigen binding agents, and compositions thereof, which target IgE, for instance: for use in treating disorders caused by IgE (such as allergic responses, or certain autoimmune responses); and, in particular, disorders caused by the interaction of IgE with the Fc?RI receptor. In particular, this invention relates to improved anti-IgE antibodies and antigen binding agents related to novel mutants of omalizumab (Xolair®). The improved anti-IgE antibodies and antigen binding agents of the invention may have improved affinity for IgE and/or an improved interaction with the C?2 domain of IgE and/or an improved modified epitope on IgE (for instance further involving the C?2 domain of IgE) and/or the ability to disassociate IgE from the Fc?RI receptor for instance at pharmaceutically-relevant concentrations.
    Type: Application
    Filed: June 26, 2024
    Publication date: January 9, 2025
    Inventors: Ralph ADAMS, Thomas Allen CESKA, Anna Marie DAVIES, Alistair James HENRY, Xiaofeng LIU, James Michael MCDONNELL, Brian John SUTTON, Marta Katarzyna WESTWOOD
  • Patent number: 12054559
    Abstract: The present invention relates to the area of improved anti-IgE antibodies and antigen binding agents, and compositions thereof, which target IgE, for instance: for use in treating disorders caused by IgE (such as allergic responses, or certain autoimmune responses); and, in particular, disorders caused by the interaction of IgE with the Fc?RI receptor. In particular, this invention relates to improved anti-IgE antibodies and antigen binding agents related to novel mutants of omalizumab (Xolair®). The improved anti-IgE antibodies and antigen binding agents of the invention may have improved affinity for IgE and/or an improved interaction with the C?2 domain of IgE and/or an improved modified epitope on IgE (for instance further involving the C?2 domain of IgE) and/or the ability to disassociate IgE from the Fc?RI receptor for instance at pharmaceutically-relevant concentrations.
    Type: Grant
    Filed: December 3, 2021
    Date of Patent: August 6, 2024
    Assignee: UCB BIOPHARMA SRL
    Inventors: Ralph Adams, Thomas Allen Ceska, Anna Marie Davies, Alistair James Henry, Xiaofeng Liu, James Michael McDonnell, Brian John Sutton, Marta Katarzyna Westwood
  • Publication number: 20240207763
    Abstract: An endcap for a filter element includes an annular plate member disposed adjacent an axial end surface of an annular filter medium of the filter element. A radially outer annular flange projects axially from a surface of the annular plate member. The radially outer annular flange includes a winglet feature extending radially outwardly in a cantilever fashion from an outer circumferential surface of the radially outer annular flange in a direction opposite to a direction in which the filter element is rotated during installation into a filter base of a filter system, with the winglet feature deflecting toward the outer circumferential surface of the radially outer annular flange through contact with a wedge-shaped protrusion projecting radially inwardly from an inner circumference of the filter base as the filter element is rotatably installed into the filter base, and springing back to its undeflected configuration after passing the wedge-shaped protrusion.
    Type: Application
    Filed: April 10, 2023
    Publication date: June 27, 2024
    Applicant: CATERPILLAR INC.
    Inventors: Jon Tyler Immel, Stephen Ellis Oedewaldt, Philip Carl Spengler, Brian John Sutton, Tony Lynn Alwardt
  • Publication number: 20220235146
    Abstract: The present invention relates to the area of improved anti-IgE antibodies and antigen binding agents, and compositions thereof, which target IgE, for instance: for use in treating disorders caused by IgE (such as allergic responses, or certain autoimmune responses); and, in particular, disorders caused by the interaction of IgE with the Fc?RI receptor. In particular, this invention relates to improved anti-IgE antibodies and antigen binding agents related to novel mutants of omalizumab (Xolair®). The improved anti-IgE antibodies and antigen binding agents of the invention may have improved affinity for IgE and/or an improved interaction with the C?2 domain of IgE and/or an improved modified epitope on IgE (for instance further involving the C?2 domain of IgE) and/or the ability to disassociate IgE from the Fc?RI receptor for instance at pharmaceutically-relevant concentrations.
    Type: Application
    Filed: December 3, 2021
    Publication date: July 28, 2022
    Inventors: Ralph ADAMS, Thomas Allen CESKA, Anna Marie DAVIES, Alistair James HENRY, Xiaofeng LIU, James Michael MCDONNELL, Brian John SUTTON, Marta Katarzyna WESTWOOD
  • Patent number: 11214627
    Abstract: The present invention relates to the area of improved anti-IgE antibodies and antigen binding agents, and compositions thereof, which target IgE, for instance: for use in treating disorders caused by IgE (such as allergic responses, or certain autoimmune responses); and, in particular, disorders caused by the interaction of IgE with the Fc?RI receptor. In particular, this invention relates to improved anti-IgE antibodies and antigen binding agents related to novel mutants of omalizumab (Xolair®). The improved anti-IgE antibodies and antigen binding agents of the invention may have improved affinity for IgE and/or an improved interaction with the C?2 domain of IgE and/or an improved modified epitope on IgE (for instance further involving the C?2 domain of IgE) and/or the ability to disassociate IgE from the Fc?RI receptor for instance at pharmaceutically-relevant concentrations.
    Type: Grant
    Filed: June 8, 2017
    Date of Patent: January 4, 2022
    Assignee: UCB BIOPHARMA SRL
    Inventors: Ralph Adams, Thomas Allen Ceska, Anna Marie Davies, Alistair James Henry, Xiaofeng Liu, James Michael McDonnell, Brian John Sutton, Marta Katarzyna Westwood
  • Patent number: 10350523
    Abstract: A filter housing is provided. The filter housing includes a circumferential rib provided on an outer surface thereof. The filter housing also includes a first longitudinal rib provided on the outer surface thereof. The first longitudinal rib connects and extends away from the circumferential rib along a length of the filter housing. The first longitudinal rib defines a first thickness thereof. The first thickness tapers towards the circumferential rib. The filter housing further includes a second longitudinal rib provided on the outer surface thereof. The second longitudinal rib is provided opposing the first longitudinal rib. The second longitudinal rib connects and extends away from the circumferential rib along the length of the filter housing. The second longitudinal rib defines a second thickness thereof. The second thickness tapers towards the circumferential rib.
    Type: Grant
    Filed: March 6, 2017
    Date of Patent: July 16, 2019
    Assignee: Caterpillar Inc.
    Inventors: Bryant Alan Morris, Jeffrey R Ries, Brian John Sutton
  • Publication number: 20190144565
    Abstract: The present invention relates to the area of improved anti-IgE antibodies and antigen binding agents, and compositions thereof, which target IgE, for instance: for use in treating disorders caused by IgE (such as allergic responses, or certain autoimmune responses); and, in particular, disorders caused by the interaction of IgE with the Fc?RI receptor. In particular, this invention relates to improved anti-IgE antibodies and antigen binding agents related to novel mutants of omalizumab (Xolair®). The improved anti-IgE antibodies and antigen binding agents of the invention may have improved affinity for IgE and/or an improved interaction with the C?2 domain of IgE and/or an improved modified epitope on IgE (for instance further involving the C?2 domain of IgE) and/or the ability to disassociate IgE from the Fc?RI receptor for instance at pharmaceutically-relevant concentrations.
    Type: Application
    Filed: June 8, 2017
    Publication date: May 16, 2019
    Inventors: Ralph ADAMS, Thomas Allen CESKA, Anna Marie DAVIES, Alistair James HENRY, Xiaofeng LIU, James Michael MCDONNELL, Brian John SUTTON, Marta Katarzyna WESTWOOD
  • Publication number: 20180250617
    Abstract: A filter housing is provided. The filter housing includes a circumferential rib provided on an outer surface thereof. The filter housing also includes a first longitudinal rib provided on the outer surface thereof. The first longitudinal rib connects and extends away from the circumferential rib along a length of the filter housing. The first longitudinal rib defines a first thickness thereof. The first thickness tapers towards the circumferential rib. The filter housing further includes a second longitudinal rib provided on the outer surface thereof. The second longitudinal rib is provided opposing the first longitudinal rib. The second longitudinal rib connects and extends away from the circumferential rib along the length of the filter housing. The second longitudinal rib defines a second thickness thereof. The second thickness tapers towards the circumferential rib.
    Type: Application
    Filed: March 6, 2017
    Publication date: September 6, 2018
    Applicant: Caterpillar Inc.
    Inventors: Bryant Alan Morris, Jeffrey R. Ries, Brian John Sutton